The Pharma Data

JUNE 18, 2021

After one year, 47 percent of patients receiving risankizumab 360 mg achieved endoscopic response compared with 22 percent of patients in the induction-only control group (p<0.001). analysis plan), with 52 percent on risankizumab 360 mg achieving clinical remission versus 41 percent in the induction-only control group (p<0.01).

Trials 40

Trials Development Clinical Trials Clinical Trials 40

The Pharma Data

JUNE 18, 2021

All differences between the overall risankizumab dose groups and placebo are statistically significant, with p-values <0.001. Risankizumab (SKYRIZI) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. NORTH CHICAGO, Ill. , Endoscopic Response c.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Development 40

Drug Discovery World

OCTOBER 14, 2022

Arndt Aspe r ger , Senior Applications Scientist , Bruker Daltonics and M ei ke Hamester , Vice President Label-Free Technologies , Bruker Daltonics , examine how challenges in mass spectrometry for high-throughput screening can be overcome using a label-free approach. . Sample courtesy of Dr Frank H. KG, Biberach, Germany.

Drugs 52

Drugs In-Vitro Development Production 52